<DOC>
<DOCNO>1051109_business_story_5454585.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 DRL to buy Roche unit

 OUR BUREAU

 Mumbai, Nov. 8: Dr Reddys Laboratories (DRL) is acquiring the active pharmaceutical ingredient (API) business of Roche in Mexico for $59 million. 

 DRL has entered into a definitive agreement to acquire the Switzerland-based Roches bulk drug business at its state-of-the-art manufacturing site in Cuernavaca, Mexico, including all employees and business supply contracts. The total investment outlay is about $59 million, including working capital.

 The business involves the manufacture and sale of APIs, including intermediates to Roche and other innovator companies. The product portfolio comprises about 18 products, including mature APIs and a range of intermediates and steroids.

 Apart from the APIs which would now come under its fold, the acquisition would add unique steroids manufacturing capabilities to DRL. The Cuernavaca site at Mexico employs nearly 340 people and has been inspected by the USFDA and other international regulatory agencies.

 DRL chief executive officer G.V. Prasad said: With the acquisition of Roches API business at the Mexico site, Dr Reddys will emerge as a leading player in custom pharmaceutical services (CPS) business and position itself as a partner of choice for innovator companies across the globe with service offerings spanning the entire value chain of pharmaceutical services.

 Prasad noted the acquisition would provide an opportunity for the companys CPS business to grow from $10 million to $100 million over the next 18 months. 

 The integration of these businesses ? people and technology; the expertise of the management team and manufacturing capability, with that of DRLs strengths in process chemistry and world class research will provide a strong foundation to drive the next wave of growth in our CPS business, he added. 




</TEXT>
</DOC>